These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 8547450

  • 1. Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.
    Davila R, Gonzalez MA, Zumarraga M, Andia I, Guimon J, Silva RR, Friedhoff AJ.
    Biol Psychiatry; 1995 Aug 15; 38(4):267-9. PubMed ID: 8547450
    [No Abstract] [Full Text] [Related]

  • 2. Schizophrenia: gender, family risk, and plasma homovanillic acid.
    Dávila R, Zumárraga M, González-Torres MA, Andía I, Zamalloa MI, Basterreche E, Guimón J, Friedhoff AJ.
    Am J Med Genet; 1995 Apr 24; 60(2):154-6. PubMed ID: 7485251
    [Abstract] [Full Text] [Related]

  • 3. Plasma catecholamine metabolites and early response to haloperidol.
    Bowers MB, Swigar ME, Jatlow PI, Goicoechea N.
    J Clin Psychiatry; 1984 Jun 24; 45(6):248-51. PubMed ID: 6725216
    [Abstract] [Full Text] [Related]

  • 4. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
    Newcomer JW, Riney SJ, Vinogradov S, Csernansky JG.
    Psychopharmacol Bull; 1992 Jun 24; 28(1):101-7. PubMed ID: 1609034
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol.
    Brown AS, Gewirtz G, Harkavy-Friedman J, Cooper T, Brébion G, Amador XF, Malaspina D, Gorman JM.
    Neuropsychopharmacology; 1997 Nov 24; 17(5):317-25. PubMed ID: 9348547
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The interaction between superoxide dismutase and prolactin is involved in response to haloperidol and risperidone treatment in schizophrenia: a double-blind and randomized study.
    Zhang XY, Zhou DF, Cao LY, Wu GY, Shen YC.
    J Clin Psychopharmacol; 2006 Feb 24; 26(1):103-5. PubMed ID: 16415724
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Impact of neuroleptic medications on continuous performance test measures in schizophrenia.
    Epstein JI, Keefe RS, Roitman SL, Harvey PD, Mohs RC.
    Biol Psychiatry; 1996 May 15; 39(10):902-5. PubMed ID: 8860194
    [No Abstract] [Full Text] [Related]

  • 11. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K, Tsuchida K, Kanzaki A, Ujike H, Hamamura T, Kondo K, Mutoh S, Miyanagi K, Kuroda S, Otsuki S.
    Biol Psychiatry; 1995 Nov 15; 38(10):639-48. PubMed ID: 8555375
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
    Suzuki E, Kanba S, Koshikawa H, Nibuya M, Yagi G, Asai M.
    J Psychiatry Neurosci; 1996 May 15; 21(3):167-71. PubMed ID: 8935328
    [Abstract] [Full Text] [Related]

  • 14. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
    Dávila R, Zumárraga M, Basterreche N, Arrúe A, Anguiano JB.
    Psychiatry Res; 2007 May 30; 151(1-2):163-8. PubMed ID: 17434602
    [Abstract] [Full Text] [Related]

  • 15. Relationship of plasma HVA and treatment response in a large series of patients with schizophrenia.
    Davila R.
    Clin Neuropharmacol; 1992 May 30; 15 Suppl 1 Pt A():519A-520A. PubMed ID: 1354057
    [No Abstract] [Full Text] [Related]

  • 16. Fluperlapine vs haloperidol: a comparison of their neuroendocrinological profiles and the influence on serum lipids.
    Fleischhacker WW, Stuppäck C, Moser C, Schubert H, Hinterhuber H.
    Pharmacopsychiatry; 1986 May 30; 19(3):111-4. PubMed ID: 2873601
    [Abstract] [Full Text] [Related]

  • 17. Evolution of plasma homovanillic acid (HVA) in chronic schizophrenic patients treated with haloperidol.
    Galinowski A, Poirier MF, Aymard N, Leyris A, Beauverie P, Bourdel MC, Loo H.
    Acta Psychiatr Scand; 1998 Jun 30; 97(6):458-66. PubMed ID: 9669519
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S, Iwamoto N, Arai H.
    Biol Psychiatry; 1997 Apr 15; 41(8):857-64. PubMed ID: 9099412
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.